TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01311661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol medium daily dose once daily and placebo
Description: Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
Study: NCT03670628

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave therapy
Description: Each therapy session, lasting about 20 minutes, will deliver 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham shockwave therapy
Description: Each therapy session, lasting about 20 minutes, will deliver sham shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
Study: NCT00832806

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended IVR (integrated voice response technology)
Description: See detailed description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline (Champix)
Description: See detailed description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline (Champix)
Description: See detailed description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IVR treatment
Description: See detailed description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IVR treatment
Description: See detailed description
Study: NCT01248975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP/SAL 250/50mcg BID
Description: FP/SAL 250/50mcg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP/SAL 250/50mcg BID
Description: FP/SAL 250/50mcg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP/SAL 250/50mcg BID
Description: FP/SAL 250/50mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 200mg QD (AM)
Description: GSK2190915 200mg QD (AM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg QD (AM)
Description: GSK2190915 100mg QD (AM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast 10mg QD (PM)
Description: Montelukast 10mg QD (PM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets (2) (AM)
Description: Placebo tablets (2) (AM)
Study: NCT02013219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
Study: NCT01248975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets (2) (AM)
Description: Placebo tablets (2) (AM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule (PM)
Description: Placebo capsule (PM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule (PM)
Description: Placebo capsule (PM)
Study: NCT01365611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
Study: NCT03469804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
Study: NCT04185727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised strength training
Description: 12 weeks supervised strength training exposure. The study will allocate patients to groups consisting of 4 members who receive strength training for 12 weeks. The strength training program will consist of three weekly supervised strength exercise sessions, each 40-60 min of duration, which starts with a 10 min warm-up and are completed with a meditation/relax session.
Study: NCT04632719

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19
Description: Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19
Description: Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.
Study: NCT02222324

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 placebo tablets matching E2609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: E2609 will be administered as 8 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: E2609 will be administered as 8 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered as 1 tablet with 7 tablets of placebo matching E2609
Study: NCT02151201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination video education
Description: Influenza vaccination video education

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hand washing video education
Description: Hand washing video education
Study: NCT01223677

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rumination Focused CBT
Description: see arms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rumination Focused CBT
Description: see arms
Study: NCT01674855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-G-CSF
Description: Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
Study: NCT01699828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: The buspirone will be given once as a tablet and encapsulated for blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: The buspirone will be given once as a tablet and encapsulated for blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: The buspirone will be given once as a tablet and encapsulated for blinding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
Study: NCT04391907

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPL
Description: Intense pulse light (IPL) laser is used for the treatment of dry eye originated from meibomian gland dysfunction. IPL laser will be performed to patients who are planned to cataract surgery to improve dry eye.
Study: NCT02566512

Intervention type: OTHER
Group type: OTHER
Intervention: Tracheostomy cuff inflation.
Description: With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.

Intervention type: OTHER
Group type: OTHER
Intervention: Tracheostomy cuff deflation
Description: With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
Study: NCT00702676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: Tablet, Oral, once daily
Study: NCT04741620

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)
Description: 10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)
Description: 10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)
Description: 10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)
Description: 10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)
Description: 10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)
Description: 10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.
Study: NCT02959762

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control
Description: two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
Study: NCT01835860

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostate artery embolization
Study: NCT03067103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
Study: NCT02959762

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)
Description: one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Description: two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
Study: NCT03106805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early insertion
Description: insertion at 4th postpartum week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: late insertion
Description: insertion at 6th postpartum week
Study: NCT03292328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait List Control
Description: Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
Study: NCT01887691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
Study: NCT01143311

Intervention type: GENETIC
Group type: OTHER
Intervention: Arm A
Description: 4 distinct biopsies will be taken~1. in a non UV-exposed area (inner arm)~2. in a UV-exposed area (external surface of the forearm)~3. in a pretumoral region (actinic keratosis)~4. inside the tumor
Study: NCT02411903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin and clopidogrel
Description: Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
Study: NCT03067103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
Study: NCT02411903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin and clopidogrel
Description: Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
Study: NCT03769922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive mesenteric resection
Description: The mesentery is resected avoiding the root region.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limited mesenteric excision
Description: The mesentery is retained.
Study: NCT03327545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: Neural mobilization on the right side of the craniocervical region for a total of 12 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft tissue techniques and Stretching
Description: Soft tissue techniques and Stretching on the right side of the craniocervical region for a total of 12 minutes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Did not receive any treatment.
Study: NCT03067103

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
Study: NCT02602067

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 131I-Tenatumomab
Description: I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
Study: NCT00609141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02493868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
Study: NCT01841151

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCP training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live Z-score training
Study: NCT01209338

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Health education
Description: Health education about HPV infection, HPV vaccine and cervix cancer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education about HPV infection, HPV vaccine and cervix cancer.
Study: NCT02254096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 1696 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 1696 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 1696 BS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal (HFM)
Study: NCT02493868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram (Oral antidepressant)
Description: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
Study: NCT05409274

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT02604732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal hernia repair with perioperative Aspirin
Description: Patients undergoing laparoscopic inguinal hernia repair will continue on Aspirin perioperatively
Study: NCT02493868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram (Oral antidepressant)
Description: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
Study: NCT00147498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at a dose of 5 mg BID for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at a dose of 15 mg BID for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 30 mg BID for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT04074655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Driving Simulator in a Virtual Reality Environment
Description: Driving simulator in virtual reality environment is a game with the several level of difficulty and the goal of improving the cognition level of participants in general and their spatial cognition in particular. Moreover this game, will have a positive effect on its users' mood as well.